CNP analogue-1

CNP analogue-1 (Compound 65) (200 nmol/kg; intravenous bolus) significantly enhances myocardial systolic and diastolic function in healthy male Sprague-Dawley rats without altering heart rate, indicating its potential to improve cardiac dynamics in patients with heart failure with preserved ejection fraction^[1].
CNP analogue-1 (102-323 nmol/kg; intravenous injection; subcutaneous injection) exhibits a prolonged plasma elimination half-life and high subcutaneous bioavailability in healthy male Sprague-Dawley rats, and achieves detectable target engagement via elevation of cGMP^[1].
CNP analogue-1 (45-60 nmol/kg; intravenous injection; subcutaneous injection) exhibits a long plasma elimination half-life and high subcutaneous bioavailability in healthy female Göttingen minipigs, supporting its potential for once-weekly administration^[1].
CNP analogue-1 (30-300 nmol/kg; intravenous bolus injection) exhibits favorable acute hemodynamic profiles in healthy male Sprague-Dawley rats, with no change in MAP and only a slight, statistically significant increase in HR observed at the two highest tested doses^[1].